UnknownPHASE1, PHASE2NCT05940545
UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF
Studying Crimean-Congo hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Liverpool School of Tropical Medicine
- Principal Investigator
- Lucy E Read, PhD, MRCPLiverpool School of Tropical Medicine
- Intervention
- Favipiravir(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2023
Study locations (1)
- Ankara Oncology Training and Research Center, Ankara, Yenimahalle, Turkey (Türkiye)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05940545 on ClinicalTrials.govOther trials for Crimean-Congo hemorrhagic fever
Additional recruiting or active studies for the same condition.